Karl Paul Link
||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (March 2013)|
Training and early career
He was born in LaPorte, Indiana to a Lutheran minister of German descent as one of ten children. He was schooled locally, and attended the University of Wisconsin–Madison, where he studied agricultural chemistry at the College of Agriculture from 1918 to 1925, obtaining an MS in 1923 and a PhD in 1925. He was then chosen by the national Education Board for a postdoctoral scholarship, and relocated to Europe. He briefly worked with carbohydrate chemist Sir James Irvine at the University of St Andrews in Scotland and from 1926 with Fritz Pregl, inventor of microchemistry and Nobel Laureate. Finally he spent several months with organic chemist and future Nobel laureate Paul Karrer in the latter's lab in Zurich; during this period Link suffered from tuberculosis, requiring recuperation in Davos. Around this time he may have acquired his taste for dressing eccentrically.
He was offered an assistant professorship at the University of Wisconsin–Madison in 1927, and was promoted to associate professor in 1928. He worked initially on plant carbohydrates and resistance to disease. He married Elizabeth Feldman in 1930; they were to have three sons.
In the subsequent years, most of his research focused on plant carbohydrates. However, the most fruitful period began when Ed Carson, a Wisconsin farmer, attracted Link's attention to sweet clover disease, described in 1924 by veterinarian Frank Schofield. In this condition, cows bled to death after consuming hay made from spoilt sweet clover. Carson's stock had been affected, and he brought a dead cow, blood that would not clot, and 100 pounds of sweet clover hay. Under the direction of Link, PhD students Harold Campbell, Ralph Overman, Charles Huebner, and Mark Stahmann crystallised the putative poison—a coumarin-related compound—and synthetised and tested it; it turned out to be dicumarol (3,3'-methylenebis-(4 hydroxycoumarin)).
Warfarin, one of the several compounds synthesised as part of the coumarin research, was patented in 1945 with the Wisconsin Alumni Research Foundation, Link and researchers Stahlmann and Ikawa jointly owning the patent. Initially marketed as rat poison, warfarin would later, in the 1950s, become the second most important anticoagulant for clinical use (after heparin).
Link was elected to the National Academy of Sciences in 1946. He received several awards for his work, including the 1955 Albert Lasker Award for Basic Medical Research and the 1960 Albert Lasker Award for Clinical Medical Research. He remained closely involved in the biochemistry of warfarin and related compounds.
His work in later years was hampered by poor health (tuberculosis). Nevertheless he remained a full professor until 1971, when he retired. He was a lifelong pioneer of liberal causes, and his wife was active in the pacifist movement.
Link died from heart failure in 1978.
- Link KP, Tottingham WE. Effects of the method of desiccation on the carbohydrates of plant tissue. J Am Chem Soc 1923;45:439-47.
- Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem 1941;138:21-33.
- Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem 138:513-27.
- Link KP. The discovery of dicumarol and its sequels. Circulation 1959;19:97-107. PMID 13619027.
- Burris RH. "Karl Paul Link". In: Biographical Memoirs: v. 64. National Academy Press, 1994. ISBN 0-309-04978-4.